PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
December 16, 2020 14:56 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches...
BES_Mark.jpg
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
October 20, 2020 19:00 ET | Bragar Eagel & Squire
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...
BES_Mark.jpg
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
October 15, 2020 20:00 ET | Bragar Eagel & Squire
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...
logo.png
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
March 10, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, March 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Celgene May Also Want to Take Notice of PharmaCyte Biotech
July 24, 2015 09:00 ET | PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 24, 2015) - A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a...
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
May 07, 2014 09:00 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA...
Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist
May 05, 2014 09:00 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 5, 2014) - Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer...
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
April 17, 2014 08:45 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 17, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical...
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
February 19, 2014 09:00 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
December 16, 2013 09:15 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...